Aratana Therapeutics (PETX) Misses Q1 EPS by 10c

Aratana Therapeutics (NASDAQ: PETX) reported Q1 EPS of ($0.52), $0.10 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $172 thousand versus the consensus estimate of $140 thousand.

For earnings history and earnings-related data on Aratana Therapeutics (PETX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M